Travere licenses Everest's BTK inhibitor with $112.5M upfront, up to $1.03B milestones

Travere Therapeutics, Inc.

Exclusive license for civorebrutinib (BTK inhibitor) outside China and select East/Southeast Asia countries.
Upfront payment of $112.5M; potential milestones up to ~$1.03B across up to five indications.
Tiered royalties from high single-digit to double-digit percentages on net sales in Territory.
Travere responsible for development and commercialization in Territory; global trial costs shared with Everest.
Deal effective upon HSR clearance; Travere can terminate and get upfront refund if tech transfer fails.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Travere Therapeutics, Inc. entered into Agreement with Everest Medicines (Singapore) Pte. Ltd. valued at upfront payment of $112.5 million (effective 2026-06-01).

Action: entry
Agreement: license
Counterparty: Everest Medicines (Singapore) Pte. Ltd.
Value: upfront payment of $112.5 million
Effective: 2026-06-01

Exact text from the filing

On June 1, 2026, Travere Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “Agreement”) with Everest Medicines (Singapore) Pte. Ltd. (“Everest”), pursuant to which Everest grants an exclusive license to the Company for the development and commercialization of civorebrutinib

View on SEC.gov

Browse all material agreements →

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-252474

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.